Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study

(2006) HIV/AIDS national report of I.R. Iran. Ministry of Health, Center for Disease Control and Prevention, HIV/AIDS Office. (Persian)

(2005) Protocol for evaluation of transmitted HIV drug resistance using specimens from HIV sentinel serosurveys in resource-limited settings (draft). WHO HIV ResNet

Adje C, Cheingsong R et al (2001) High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 26(5):501–506

Bennett DE, Myatt M et al (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13(Suppl 2):25–36

Bertagnolio S, Soto-Ramirez L et al (2007) HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12(1):107–113

Buckton AJ, Bissett SL et al (2008) Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother 62(6):1191–1198

Day C, Nassirimanesh B et al (2006) Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J 3:2

Duwe S, Brunn M et al (2001) Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26(3):266–273

Garrido C, Zahonero N et al (2008) Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 61(3):694–698

Harris ME, Serwadda D et al (2002) Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 18(17):1281–1290

Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111–120

Larijani B, Zahedi F et al (2005) Medical ethics in the Islamic Republic of Iran. East Mediterr Health J 11(5–6):1061–1072

McNulty A, Jennings C et al (2007) Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45(2):517–521

Naderi HR, Tagliamonte M et al (2006) Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. Infect Agent Cancer 1:4

Razzaghi EM, Movaghar AR et al (2006) Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 3:12

Richman DD, Morton SC et al (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18(10):1393–1401

Sanders-Buell E, Saad MD et al (2007) A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD. AIDS Res Hum Retroviruses 23(6):834–839

Sarrami-Forooshani R, Das SR et al (2006) Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol 78(7):853–863

Tagliamonte M, Naderi HR et al (2007) HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran. AIDS Res Hum Retroviruses 23(12):1569–1574

Vazirian M, Nassirimanesh B et al (2005) Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J 2:19

Yerly S, Vora S et al (2001) Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15(17):2287–2292

Zamani S, Kihara M et al (2006) High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr 42(3):342–346